Brown Advisory Inc. Purchases 993 Shares of Stryker Corporation (NYSE:SYK)

Brown Advisory Inc. raised its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,079 shares of the medical technology company's stock after purchasing an additional 993 shares during the quarter. Brown Advisory Inc.'s holdings in Stryker were worth $17,525,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Brighton Jones LLC increased its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Stryker by 28.1% in the 4th quarter. Assetmark Inc. now owns 1,298 shares of the medical technology company's stock worth $467,000 after purchasing an additional 285 shares in the last quarter. Proficio Capital Partners LLC grew its holdings in shares of Stryker by 46.2% during the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock valued at $596,000 after purchasing an additional 523 shares during the last quarter. Independent Advisor Alliance increased its stake in Stryker by 19.4% in the 4th quarter. Independent Advisor Alliance now owns 8,149 shares of the medical technology company's stock worth $2,934,000 after purchasing an additional 1,325 shares during the period. Finally, Sequoia Financial Advisors LLC increased its position in shares of Stryker by 7.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 12,074 shares of the medical technology company's stock valued at $4,347,000 after acquiring an additional 838 shares during the period. Institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Stryker stock traded down $5.53 during mid-day trading on Friday, reaching $389.24. 825,133 shares of the company traded hands, compared to its average volume of 1,352,494. The firm's fifty day moving average is $384.57 and its two-hundred day moving average is $376.97. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. The company has a market capitalization of $148.57 billion, a price-to-earnings ratio of 31.51, a price-to-earnings-growth ratio of 2.98 and a beta of 0.91. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $2.50 EPS. On average, equities research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker's payout ratio is 45.41%.

Insider Activity

In related news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director directly owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SYK. BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Roth Mkm raised their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Finally, Citigroup reaffirmed a "buy" rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $428.55.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.